国产福利酱国产一区二区|亚洲精品一区二区三区成人|9l肥熟女福利视频导航|91嫩草国产线永久在线观看|免费99在线视频播放|明明成人免费高清在线观看

更新于 6月25日

抗體發(fā)現(xiàn)高級經(jīng)理/副總監(jiān)

3.5-4.5萬·16薪
  • 上海浦東新區(qū)
  • 5-10年
  • 博士
  • 全職
  • 招1人

職位描述

生物藥研發(fā)抗體發(fā)現(xiàn)抗體工程人源化噬菌體雜交瘤立項
-The qualified candidate should have extensive experience in antibody discovery and in design and implement functional and cell-based assays to support antibody discovery efforts. -The successful candidate will be commanding the design, development and functional in vitro and in vivo characterization of innovative antibody-based therapeutic modalities. The applicant will lead a small group of in- house team to design and execute experiments efficiently, as well as analyze, interpret, and present data to multidisciplinary project teams. -The ideal candidate will have a deep understanding of all requirements and processes needed to advance large molecule projects through discovery and preclinical development. -A demonstrated track record of handling discovery projects and people management is essential. Technical/Skills Require -Ph.D. in antibody discovery at least 7 years drug discovery experiences. Prior experience of developing flow schemes to support antibody lead discovery and optimization -Strong interpersonal capabilities and ability to build networks internal and external Demonstrated ability to build inclusive working environment to support innovation -Familiar with CRO network -Demonstrated people management capability and capacity

工作地點

浦東新區(qū)上海復星健康科技(集團)有限公司1號樓8樓

職位發(fā)布者

孫女士/招聘主管

三日內(nèi)活躍
立即溝通
公司Logo上海復宏漢霖生物技術股份有限公司
復宏漢霖(2696.HK)是一家國際化的創(chuàng)新生物制藥公司,致力于為全球患者提供可負擔的高品質(zhì)生物藥,產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領域,已在中國上市5款產(chǎn)品,在國際上市1款產(chǎn)品,18項適應癥獲批,3個上市申請分別獲中國藥監(jiān)局、美國FDA和歐盟EMA受理。自2010年成立以來,復宏漢霖已建成一體化生物制藥平臺,高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運營全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心,按照國際藥品生產(chǎn)質(zhì)量管理規(guī)范(GMP)標準進行生產(chǎn)和質(zhì)量管控,不斷夯實一體化綜合生產(chǎn)平臺,其中,上海徐匯基地已獲得中國和歐盟GMP認證,松江基地(一)也已獲得中國GMP認證。復宏漢霖前瞻性布局了一個多元化、高質(zhì)量的產(chǎn)品管線,涵蓋20多種創(chuàng)新單克隆抗體,并全面推進基于自有抗PD-1單抗H藥漢斯狀?的腫瘤免疫聯(lián)合療法。繼國內(nèi)首個生物類似藥漢利康?(利妥昔單抗)、中國首個自主研發(fā)的中歐雙批單抗藥物漢曲優(yōu)?(曲妥珠單抗,歐洲商品名:Zercepac?,澳大利亞商品名:Tuzucip?和Trastucip?)、漢達遠?(阿達木單抗)和漢貝泰?(貝伐珠單抗)相繼獲批上市,創(chuàng)新產(chǎn)品漢斯狀?(斯魯利單抗)已獲批用于治療微衛(wèi)星高度不穩(wěn)定(MSI-H)實體瘤、鱗狀非小細胞肺癌和廣泛期小細胞肺癌,成為全球首個獲批一線治療小細胞肺癌的抗PD-1單抗,其食管鱗狀細胞癌適應癥的上市注冊申請也正在審評中。公司亦同步就16個產(chǎn)品在全球范圍內(nèi)開展30多項臨床試驗。
公司主頁